SNO Pediatric Oncology Meeting

Dianhydrogalactitol (VAL-083) overcomes p53-mediated chemo-resistance and displays synergy with topoisomerase inhibitors

WFNOS 2017

Clinical trials of VAL-083 in patients with chemoresistant glioblastoma

WFNOS 2017

Distinct mechanism of action of dianhydrogalactitol (VAL-083) overcomes chemoresistance in glioblastoma

AACR Annual Meeting 2017

Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Overcoming Chemoresistance in Glioblastoma

AACR Annual Meeting 2017

DNA damage response to dianhydrogalactitol (VAL-083) in p53-deficient non-small cell lung cancer cells